The Pathogenesis of Alopecia Areata in Rodent Models  by McElwee, Kevin J. et al.
REVIEWARTICLE
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Rodent models of human disease provide an important
tool in the investigation of genetic and environmental
activation factors, disease pathogenesis, and the devel-
opment of new and improved treatments. Up to 20%
of aged C3H/HeJ mice and 70% of Dundee Experimen-
tal Bald Rats (DEBR) develop alopecia areata (AA), a
nonscarring, in£ammatory hair loss disease with a sus-
pected autoimmune pathogenesis. These rodent models
are currently employed in determining the genetic basis
of AA, understanding the mechanisms of disease initia-
tion and progression, and de¢ning potential endogen-
ous and environmental in£uences. Induction of AA by
skin graft transfer between a¡ected and una¡ected mice
has been employed to examine skin and immune sys-
tem changes during AA pathogenesis. Manipulation of
in£ammatory cells in vivo indicates AA is primarily a
cell mediated disease with auto-antibody production as
a secondary event. Whether the AA activating factors
are exogenous or endogenous antigens, or involve
normal or aberrant epitope expression remains to be
elucidated. However, current research suggests a self
contained disease cycle involving four key events: (1)
Failure of the putative anagen stage hair follicle im-
mune privilege and exposure of hair follicle located
AA inciting epitopes to the immune system; (2) Anti-
gen presentation, costimulation, and activation of re-
sponsive lymphocytes by antigen presenting cells; (3)
Activated in£ammatory cell migration to, and in¢ltra-
tion of, hair follicles; (4) The subsequent disruptive
actions of the in£ammatory cell in¢ltrate on the hair
follicles. Each of these events is vulnerable to therapeu-
tic intervention, and rodent models will be fundamen-
tally involved in developing new treatments for AA.
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nity. JID Symposium Proceedings 8:6 ^11, 2003
A
lopecia areata (AA) is regarded as a nonscarring, in-
£ammatory disease of the hair follicle.While there is
no obvious clinically visible in£ammation in most
AA patients, histopathological examination reveals
anagen stage hair follicles to be a¡ected by a peri-
and intrafollicular in£ammatory cell in¢ltrate of primarily
CD4þ and CD8þ cells (Perret et al, 1984; Ranki et al, 1984). In
association with active disease, there is increased expression of
class I and II MHC antigens along with increased numbers of
antigen presenting cells (macrophages, Langerhans’ cells) in AA
lesions (Wiesner-Menzel and Happle, 1984). Circulating high titer
IgG isotype autoantibodies capable of binding hair follicle speci-
¢c antigens have been identi¢ed in AA a¡ected individuals and
deposits of immunoglobulin and complement around hair folli-
cles, particularly at the margin of active lesions, have been ob-
served (Bystryn et al, 1979; Tobin et al, 1994; Tobin et al, 1997a).
E¡ective therapies for AA involve modulation or suppression of
immune cells in the skin (Freyschmidt-Paul et al, 2001). These and
other circumstantial and indirect evidence suggest that AA devel-
opment may involve autoimmune disease mechanisms and tar-
geting of as yet unidenti¢ed antigens within anagen stage hair
follicles (McElwee et al, 1999a).
Human AA is a complex disease where clinical presentation
varies considerably between individuals. In part, this re£ects the
mixed genetic background of the patients and the ‘‘dirty environ-
ment’’ in which people live involving random exposure to patho-
gens, toxic compounds, various diets, and more. Inbred rodents
living in a controlled environment provide useful models to ex-
plore speci¢c aspects of disease and to perform ‘‘clean’’, controlled
experiments that cannot be conducted with humans. Information
gained from such models helps de¢ne how disease develops
and progresses, and most importantly provides clues as to
how they can be treated better. Due to the wide heterogeneous
clinical presentation and also probable variations in the patho-
genic mechanisms of development in subsets of AA-a¡ected
humans, information derived from inbred rodent models may
not be applicable to all instances of human AA. However, an
accurate rodent model should provide information relevant to the
majority of cases (Fig 1).
AA IN RODENTMODELS
In addition to isolated case reports of AA in outbred mammals,
several inbred mouse strains and substrains have been identi¢ed
with AA-like hair loss of variable expression frequency (McEl-
wee et al, 1998a; McElwee et al, 1999b). However, C3H/HeJ mouse
AA is the most extensively characterized and most commonly
utilized model. AA-like hair loss was ¢rst observed in a C3H/
HeJ mouse colony with a frequency of 0.25% for females and
0.035% for males, at ¢ve months of age (Sundberg et al, 1994a;
Sundberg et al, 1994b). By 18 months, the frequency of AA in-
creased to 20%. Typically ¢rst onset of AA develops from four
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months of age in females compared to six or more months in
males. The lesion is often ¢rst expressed as a large, uniform thin-
ning of hair or as multi focal sites often with symmetrical distri-
bution on the ventrum later progressing to the dorsum.
The Dundee experimental bald rat (DEBR) is derived from a
spontaneous alopecia trait ¢rst observed in BD-IX inbred rats
(Michie et al, 1991). To improve the poor fecundity of these alo-
pecic animals, the BD-IX rats were crossed withWistar rats and
the DEBR descendants of this cross were derived from full
sib-matings. Two separate sublines, one brown and one black
hooded, have been developed subsequent to theWistar cross, each
isolated and now inbred to generation F38þ 0. Each subline has
di¡erent genetic haplotypes, but common disease expression.
DEBR rats develop a full coat of hair within two weeks of
birth and hair growth continues until the rats are approximately
5 months old. First onset of AA occurs from 5 to 8 months of age
with female rats twice as likely as males to express the lesion and
more likely to develop extensive AA. Up to 42% of individuals
in a DEBR rat colony (70% female) can express a lesion that may
persist as a slight thinning of the pelage or extensive patches of
hair loss. Near total loss of hair is attained in 15% of a¡ected rats,
almost exclusively female. Typically, alopecia on the head spreads
backwards around the eyes to merge with alopecia on the £ank
and reaches a chronic stable phase at 10^14 months of age. Ap-
proximately 25% of lesional DEBR rats have nail deformities
with the frequency of expression equally distributed between
males and females. The nails typically present as exceptionally
long and twisted (onchogryphosis) with minor irregularities on
the nail surface.There is no apparent correlation between hair loss
extent and nail deformities.
Histologically, both AA-a¡ected mouse and rat skin initially
exhibit increased anagen stage hair follicle activity as the lesions
aggressively develop and expand. Later, in the chronic, stable dis-
ease phase, hair follicles are observed predominantly in a telogen
state. Focal peri- and intrabulbar mononuclear cell in¢ltrates are
associated with only anagen stage hair follicles; telogen hair folli-
cles are una¡ected. The in¢ltrates consist primarily of CD4þ,
CD8þ cells and macrophages (Michie et al, 1990; Sundberg et al,
1994a; Sundberg et al, 1994b; Zhang and Oliver, 1994). The peri-
follicular in¢ltrate may be located from the region of the bulbar
follicular epithelium up to the level of the sebaceous glands.
Pigmentary incontinence and follicular dyskeratosis are particu-
larly prominent in rodents with lesions of prolonged duration.
Research has revealed hair follicle speci¢c autoantibodies to be
present in signi¢cantly elevated concentrations in a¡ected DEBR
and C3H/HeJ mice. As with humans, hair follicle speci¢c auto-
antibodies are also occasionally present in rats and mice without
hair loss (McElwee et al, 1996a; McElwee et al, 1996b; Tobin et al,
1997a; Tobin et al, 1997b).
DISEASE MODELS FOR ALOPECIA AREATA
Previously, it has been hypothesized that AA may be modeled on
one of three basic mechanisms. (1) AA is the result of infection
localized to the hair follicle activating an immune response
against the infectious agent with secondary disruption of hair
follicle growth (Skinner et al, 1995a; Skinner et al, 1995b); (2)
A fundamental defect in the immune system leads to failure of
tolerance towards hair follicle speci¢c antigens and subsequent
development of a classic autoimmune disease scenario (Mitchell
and Krull, 1984); (3) A fundamental defect in hair follicle function
exists in patients with in£ammation being a secondary event
(Goldsmith, 1991; Nutbrown et al, 1996).
In each of the above models the AA inciting antigen(s) tar-
geted by the immune system are apparently located within hair
follicles and must be exposed to immuno-surveillance for onset
of AA to occur.Whether the antigenic target within hair follicles
is endogenous or exogenous has yet to be de¢ned. Exogenous
antigen activation of AA such as hair follicle localization of cyto-
megalovirus has been suggested (Skinner et al, 1995a; Skinner
et al, 1995b). However, mouse CMV and other candidate infec-
tious agent contamination of rodent model skin could not be
con¢rmed (McElwee et al, 1998b). There is no circumstantial evi-
dence of direct infectious agent involvement, as AA is not trans-
ferred between cohabiting rodent breeding pairs and littermates
even after more than a year of continuous contact (personal ob-
servations). AA could not be described as an autoimmune disease
if hair follicle localized exogenous antigens were identi¢ed as the
direct activator of AA (McElwee et al, 1999a). Equally, an endo-
genous hair follicle expressed target antigen does not preclude the
involvement of environmental antigens in AA onset. Theoreti-
cally, exogenous antigens may activate AA by mimicry of endo-
genous epitopes eliciting an autoimmune reaction. In addition,
general viral and vaccine load may be a susceptibility or severity
modi¢er of AA.
Transient in£ammation of AA a¡ected hair follicles is readily
apparent in rodents, restricted to anagen stage hair follicles. The
inciting factor for hair follicle in£ammation may be similarly
transiently expressed. In£ammation could potentially be a purely
secondary phenomenon in response to a defect of anagen stage
hair follicles or a transient infectious agent that directly promotes
AA. However, whether the inciting hair follicle antigen is truly
endogenous or exogenous, and AA is truly autoimmune in nat-
ure, there is research evidence from rodent models indicating in-
£ammation is the primary promoter and maintainer of hair loss
during development and chronic, persistent phases of AA:
(1) Immunosuppressive agents have been used successfully in AA
a¡ected rodents to promote hair regrowth (Sainsbury et al,
1991; Oliver and Lowe, 1995; McElwee et al, 1997; Freyschmidt-
Paul, in press). However, such drugs are nonspeci¢c in their
action and may have a direct hair growth promoting action
as well as immunosuppressive properties. This is the case for
Cyclosporin A and Tacrolimus (Yamamoto et al, 1994; Jiang
et al, 1995) and so the bene¢cial e¡ects of these agents on AA
can only be taken as circumstantial evidence of an in£amma-
tory, controlling mechanism for AA.
(2) Of greater signi¢cance, CD4þ and CD8þ cell depletion
using monoclonal antibodies in both AA a¡ected C3H/HeJ
mice and DEBR permitted hair regrowth whereas isotype
matched irrelevant MoAbs had no e¡ect on AA (McElwee
et al, 1996c; McElwee et al, 1999c; Carroll et al, 2002). This sug-
gests CD4þ and CD8þ cells are signi¢cantly involved in
maintaining the AA lesions.
Figure1. Relevance of rodent models to human alopecia areata.
Human alopecia areata involves considerable variation in phenotype and
probably also involves genotype heterogeneity within a restricted range.
An inbred rodent model may not represent all human phenotype or geno-
type presentations, but will be relevant to a subset of alopecia areata-af-
fected individuals. Where a rodent model and human phenotype and
genotype coincides, each rodent model represents a subset of the human
population. Each rodent model may represent unique or overlapping
subsets.
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(3) In addition, inhibiting in£ammatory cell migration using
monoclonal antibodies (MoAbs) against CD44v10, com-
monly expressed on activated lymphocytes, blocks develop-
ment of AA (Freyschmidt-Paul et al, 2000).
(4) Inhibition of AA onset has also been demonstrated using
MoAbs against costimulatory antigen B7 commonly ex-
pressed on antigen presenting cells (APCs) (Carroll et al, 2002).
(5) Grafting AA a¡ected skin to histocompatible C3Smn.
CB17-Prkdcscid/J (C3H SCID) mice induced neutrophil in-
£ammation of anagen stage hair follicles in graft and host
skin, but in the absence of CD4þ and CD8þ cells hair re-
growth was observed from grafted skin and no hair loss de-
veloped in host skin. (McElwee et al, 1998c).
(6) AA can be transferred from AA a¡ected mice to una¡ected
mice by injection of skin draining lymph node or spleen de-
rived cells (Carroll et al, 2002).
(7) Further con¢rmation of CD4þ and CD8þ cell importance
in an in£ammatory mediated mechanism of AA may come
from a human ^ Prkdcscid/Prkdcscid mouse xenograft model.
Human AA a¡ected skin grafted to Prkdcscid/Prkdcscid mice
permits hair regrowth. AA can be re-induced in the skin
graft after injection of in vitro activated lymphocytes (Gilhar
and Krueger, 1987; Gilhar et al, 1998; Gilhar et al, 1999). How-
ever, whether the SCID model approach induces hair loss
mimicking AA or whether the hair loss is a scarring alopecia
remains to be elucidated. Rodent AA perpetuation is in£am-
matory cell mediated and targets anagen stage hair follicles,
but the studies described above reveal little about the initial
events in AA pathogenesis.
HYPOTHESES FOR ALOPECIA AREATA PATHOGENESIS
Several hypotheses for AA development have been suggested
from focal infection and toxic substance exposure to re£ex nerve
irritation, emotional disturbance and endocrine hormone action
(McElwee et al, 1998a). Recently, studies revealed gonadal hor-
mones may play a role in susceptibility to AA onset in C3H/HeJ
mice.While estrogen supplementation apparently accelerated the
rate of AA progression, dihydrotestosterone supplementation en-
tirely inhibited onset of AA (McElwe et al, 2001). However,
while such epigenetic factors may play a signi¢cant role in disease
susceptibility and severity, they are likely secondary disease
modi¢ers to the primary disease mechanism. In light of current
evidence, recent AA pathogenesis hypotheses have focused on in-
£ammatory cell mediation with autoimmune disease as an under-
lying principle. The most detailed hypothesis to date (Paus
et al, 1993) suggested onset of AA may involve a two stage process
whereby inciting antigens within the hair follicle are abnormally
exposed by subclinical immune system activity and subsequent
presentation of these antigens activates a second, much larger im-
mune system response resulting in the overt, clinical hair loss dis-
ease. In part this hypothesis relies upon the putative transient
immune privilege attributed to anagen stage hair follicles and its
breakdown in AA (Christoph et al, 2000).
Small skin grafts from rat AA lesions transferred to prelesional
DEBR rats enabled regrowth of normal hair from initially dys-
trophic hair follicles. Reciprocal studies in both rat and mouse
models resulted in normal haired skin grafts swiftly developing
a dystrophic state when transferred to mature, lesional animals.
AA a¡ected rat skin grafts to nude mice and AA a¡ected mouse
skin grafts to C3H SCID mice enabled the dystrophic hair folli-
cles in the grafts to regrow hair (Oliver, unpublished observa-
tions; McElwee et al, 1998c). This demonstrated the importance
of an immune component in the perpetuation of hair loss
and the importance of systemic immune in£uence over the loca-
lized a¡ected hair follicles. The studies suggest that the AA-like
lesions in rodents are a true, nonscarring form of alopecia that
can potentially be reversed.
Intriguingly, grafting skin from AA a¡ected mice to unaf-
fected C3H/HeJ mice transfers or induces onset of AA typically
8^10 weeks after grafting (McElwee et al, 1998c). Prior to overt
hair loss there is a gradual buildup of in£ammation in skin, com-
paratively unfocused at ¢rst, but later forming a peri- and intra-
follicular distribution. This time delay between surgery and hair
loss may be consistent with the Paus hypothesis (Paus et al, 1993).
Analysis of this time delay from skin grafting, as the disease acti-
vation event, to onset of hair loss should provide signi¢cant clues
as to the mechanisms involved in AA onset.
ALOPECIA AREATA PATHOGENESIS IN
RODENTMODELS
The anagen stage hair follicle has been suggested as a transient
immune privileged site (Barker and Billingham, 1977; Westgate
et al, 1991; Christoph et al, 2000). Normal anagen hair follicles
express very low or no MHC class I or class II antigens, but
during human and rodent AA expression signi¢cantly increases
(Messenger and Bleechen, 1985; Br˛cker et al, 1987; Khoury et al,
1988). Increased MHC expression may result in presentation of
hair follicle located antigens not normally exposed to the im-
mune system. However, it has been indicated that MHC expres-
sion in hair follicles is a secondary phenomenon, developing
subsequent to in£ammatory cell in¢ltration. The hair follicle also
incorporates a physical and biochemical barrier to immune sur-
veillance, the basement, or glassy, membrane. For in£ammatory
cells to penetrate to intrafollicular positions in AA, these barriers
must ¢rst be breached.
In the mouse model of AA, the putative immune privilege of
hair follicles provides little resistance to activated in£ammatory
cells. Normal haired C3H/HeJ, histocompatible C3H SCID or
C3H/OuJ skin grafted to AA a¡ected skin is rapidly in¢ltrated
by in£ammatory cells with almost immediate hair follicle dystro-
phy and inhibition of visible hair ¢ber growth (McElwee et al,
1998c). This suggests that the exciting antigen targets for activated
in£ammatory cells are normally expressed in anagen hair follicles
of C3H mouse strains. However, it is possible that C3H/HeJ mice
and histocompatible substrains inherently express antigens that
are not normally expressed in unrelated mouse strains. Equally,
it is possible that C3H mouse strains have a defect in the hair fol-
licles’ immune privilege resulting in a greater general susceptibil-
ity towards AA development. While in£ammatory cells are
apparently the controlling mediators of AA lesion development,
the possibility of hair follicle defects cannot be ruled out. The
commentary of Goldsmith (Goldsmith, 1991) may yet be applic-
able to AAwith some modi¢cation.
These and other evidence demonstrate rodent AA is an in£am-
matory mediated, ‘‘organ’’ speci¢c disease and are consistent with
an autoimmune pathogenesis. Although the inciting agents with-
in anagen hair follicles have yet to be de¢ned, a basic principle of
disease development emerges from rodent model research (Fig 2).
Both genetic and environmental factors can contribute to the
general degree of AA susceptibility in any one individual. The
combined e¡ects may potentially act on the hair follicle and/or
on aspects of the immune system. As environmental factors
change with time, gene activity may be modi¢ed through gene^
environment interaction and additively a¡ect an individual’s
susceptibility to AA onset. Once AA has developed, genetic
and environment interaction may still in£uence the rate of lesion
progression, end stage extent of hair loss, lesion duration, and
resistance to treatment.
Onset of AA requires exposure of unknown inciting epitopes
within hair follicles subsequently taken up by antigen presenting
cells (APCs) and presented to lymphocytes in draining lymph
nodes and possibly in other immune system organs such as the
spleen (Fig 2). Activated in£ammatory cells migrate from organs
of the immune system and in¢ltrate the skin and anagen stage
hair follicles. Their disruptive e¡ects, mediated in part through
Fas ^ Fas ligand binding, result in hair follicle dystrophy and con-
tinued antigen exposure in association with MHC expression.
This may expose numerous antigenic epitopes for uptake by
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APCs and further stimulation of autoreactive lymphocytes.With
repeated cycles of hair follicle disruption, antigen exposure, and
lymphocyte activation, epitope spreading may occur and a wider
range of antigens and hair follicle structures may be targeted
(Chan et al, 1998). This disease cycle is self-perpetuating and the
initial disease activating agents need not persist for AA lesions to
continue. Hypothetically, the activating antigenic epitopes may
only be transiently expressed.
PRACTICAL AND HYPOTHETICALTREATMENT
APPROACHES
If AA pathogenesis is founded upon an in£ammation mediated
concept, then there are several possible approaches to new treat-
ment development (Fig 3):
(1) Drug treatments for AA are predominantly immunosuppres-
sive or immunomodulatory in their e¡ect. Immunosuppres-
sive agents restrict in¢ltration of the skin and hair follicles by
activated in£ammatory cells (Gupta et al, 1990; Oliver and
Lowe, 1995; McElwee et al, 1997), while contact sensitizing
agents alter the skin environment such that the action of in-
£ammatory cells on hair follicle growth is down-regulated
(Ho¡mann et al, 1994; Ho¡mann and Happle, 1999; Freyschmidt-
Paul et al, 1999).
Remission of mouse and rat AA has been induced using
several immunomodulatory compounds. Intralesional injec-
tion of triamcinolone acetonide, PUVA (methoxysporalen
plus UV A light), and treatment with the topical sensitizers
dinitrochlorobenzene (DNCB), diphenylcyclopropenone
(DPCP), and squaric acid dibutyl ester (SADBE) have each
induced hair growth in one or both models (Sundberg et al,
1994a; Sundberg et al, 1994b; Oliver and Lowe, 1995; Sund-
berg et al, 1995; McElwee et al, 1997; Freyschmidt-Paul et al,
1999; Shapiro et al, 1999; Gardner et al, 2000). These and other
evidence demonstrate a good correlation between rodent
models and human AA and indicate hair loss may similarly
be due to in£ammatory autoimmune mediated, hair follicle
speci¢c mechanisms.
(2) Minoxidil, and also in part cyclosporine and tacrolimus, have
direct hair follicle growth promoting e¡ects (Yamamoto et al,
1994; Jiang et al, 1995). As such, an additional secondary AA
therapeutic approach is to treat the symptom of hair loss
using agents with direct action on the a¡ected hair follicles
(Fiedler-Weiss, 1987; Price, 1987). However, the relatively non-
speci¢c action, potential for side-e¡ects, and limited response
in many individuals to current treatments means new thera-
peutic approaches are required. In the short to mid term, new
and improved drug treatments will become available, primar-
ily derived from pharmaceutical research and developments
in other autoimmune and in£ammatory diseases. With a
greater understanding of immunosuppressive agents, contact
sensitizers and hair growth promoting drugs and their modes
of action, more re¢ned and potent drugs may become avail-
able that are suitable for use in AA.
(3) Theoretically, autoimmune or in£ammatory disease mechan-
isms can be modulated in several ways. By extension of our
understanding of in£ammatory mechanisms and drug action
upon them, speci¢c pathways may be targeted. Observations
on contact sensitization treatment have led to speculation that
future treatments could involve modifying the skin and hair
follicle biochemical environment. Injection of interleukins or
application of their respective cDNA sequences may be used
to block or modulate in£ammatory cell in¢ltration of the skin
and hair follicles. Alternatively, similar approaches may directly
promote hair growth in spite of hair follicle in£ammation.
(4) Potentially, the most challenging therapeutic approach is to
de¢ne lymphocyte clones reactive for hair follicle antigen
epitopes and either block their production (clonal deletion)
or promote tolerance (clonal anergy) (Theo¢lopoulos, 1995).
Oral tolerance has been one suggested approach in autoim-
mune disease treatment; however, without knowledge of the
antigenic targets involved in AA, such treatment approaches
are not yet viable.
(5) The blockade or modulation of antigen presentation and
costimulation by antigen presenting cells to the responsive
lymphocyte clones involved in AA may be a further focus
of new treatment approaches.
Figure 2. Alopecia areata pathogenesis and perpetuation.
Figure 3. Practical and theoretical therapeutic interventions in alo-
pecia areata pathogenesis.
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(6) Once the lymphocytes are activated, it may still be possible to
block cell migration from sites of activation to the skin and
hair follicles. Preliminary investigations in which CD44v10
was targeted with MoAbs suggest cell migration inhibition
may have potential AA treatment bene¢t (Freyschmit-Paul
et al, 2000). Other activated cell surface markers and variants
expressed during migration may be additional targets. These
approaches may be employed as both treatment and preven-
tative measures in AA susceptible individuals.
(7) Once hair follicle in£ammation is underway, several treat-
ment approaches are still possible. A potentially complicated
therapeutic intervention may involve blocking or modulat-
ing antigens expressed within anagen stage hair follicles, that
are the apparent target for in£ammatory cells, or masking
their expression. In addition to modifying the in£ammation
inciting antigen expression, inhibition of MHC expression
within hair follicles may also block AA lesion perpetuation.
(8) Finally, the mechanisms by which the in£ammatory cells ad-
versely a¡ect hair follicle activity may be targeted, including
disruption of Fas ^ Fas ligand interaction, prevention of
granzyme and perforin action, oxygen radical neutralization,
and alteration of the cytokine receptor and cytokine milieu.
CONCLUSION
Human AA is heterogeneous in its clinical presentation and also
probably in the pathogenic mechanisms of development. Multi-
ple factors may contribute to disease susceptibility, activation,
progression, and perpetuation. In£uence on disease may come
from the environment and from the genetics of the a¡ected indi-
vidual, and changes in the gene^environment interaction over
time may modify the nature of the disease. Di¡erent factors
may be important for individual cases; while genetics may be
the primary determinant in one individual, the environment
may be the major disease factor in another. It is possible that
what we currently collectively describe as AA may be a common
clinical symptom of several di¡erent mechanisms of disease
pathogenesis. Consequently, rodent models may not be the
equivalent of each and every human case, but may represent a
subset of the human population. It is possible that di¡erent ro-
dent models represent di¡erent human subgroups making com-
parative research of multiple models desirable. Where the
mechanisms of human and rodent disease are similar, so informa-
tion gained from rodent models will help de¢ne howAA is in-
itiated and progresses and will provide clues as to howAA can be
treated better.
De¢ning what comes ¢rst in the onset of spontaneous AA,
hair follicle aberration or in£ammatory cell in¢ltration may not
be practical. However, research to understand the downstream
cycle of disease pathogenesis after the activation event and disease
perpetuation is highly practical when using rodent models.While
the initiation of rodent model AA may involve a succession of
events, the perpetuation of AA is likely to be a cycle of events
and not a cascade. This is particularly relevant when the morpho-
logical target, the hair follicle, follows a cycle of proliferation and
regression.Within the cycle there are four key events: (1) hair fol-
licle located antigen exposure (be it exogenous, endogenous, nor-
mal or aberrant expression) to the immune system; (2) antigen
presentation, costimulation, and activation of responsive lympho-
cytes by APCs; (3) activated in£ammatory cell migration to and
in¢ltration of hair follicles; and (4) the action of the in£amma-
tory cell in¢ltrate on the hair follicles. Each of these events is vul-
nerable to therapeutic intervention. In addition, peripheral to the
disease cycle mechanism, the reactive lymphocyte clones may be
tolerized, deleted, or otherwise modulated.
Therapeutic intervention in the short term will involve new
and improved drug treatments to modulate hair follicle in£am-
mation and to promote hair growth. In the mid term, aspects of
the disease cycle may be targeted with cytokines, antigens, anti-
bodies, and other factors. In the long term, treatment may target
genes directly involved in the disease cycle mechanism or the
contribution of general susceptibility and severity modifying
genes. Rodent models will remain vital to understand AA and
to develop such treatments.
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